drugset / Trial / NCT06314724

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

NCT06314724

Phase 3 Completed 642 enrolled Sinovac (Dalian) Vaccine Technology Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a Phase Ⅲ, randomized, double-blind, active-controlled study to assess the immunogenicity and safety of the varicella vaccine,Live (hereinafter referred to as "varicella vaccine")manufactured by Sinovac (Dalian) Vaccine Technology Co., LTD.(hereinafter referred to as "Sinovac").

Timeline

Start
2024-02-29
Primary completion
2024-09-06
Completion
2024-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Varicella vaccine Vaccine Subcutaneous
Comparator Varivax Vaccine Subcutaneous

Indications